一分钟看懂
这是一项关于Carcinoma, Non-Small Cell Lung的I 期 / II 期研究，登记的药物或干预包括quaratusugene ozeplasmid；osimertinib；Platinum-Based Chemotherapy，当前状态为招募中。登记地点显示中国Los Angeles、Lone Tree、Urbana、Lexington等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
quaratusugene ozeplasmid；osimertinib；Platinum-Based Chemotherapy · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Valkyrie Clinical Trials · Los Angeles
- Rocky Mountain Cancer Centers · Lone Tree
- Carle Cancer Institute · Urbana
- Markey Cancer Center · Lexington
- Maryland Oncology Hematology · Rockville
- The Valley Hospital - Luckow Pavilion · Paramus
- Gabrail Cancer Center Research · Canton
- Millennium Oncology · Houston
- Virginia Cancer Specialists · Fairfax
- Virginia Oncology Associates · Norfolk
公开的入选条件
- 1. Age ≥18 years.
- 2. Histologically or cytologically documented NSCLC.
- 3. Stage III or IV NSCLC or recurrent NSCLC that is not potentially curable by radiotherapy or surgery.
- 4. The NSCLC must be epidermal growth factor receptor (EGFR) mutation positive-positive based on results from most recent tissue biopsy or most recent evaluation of circulating tumor DNA.
- 5. Achieved clinical response to osimertinib for ≥4 months, which can be a response of stable disease. Must have a minimum of a 10-day osimertinib washout completed at the time of enrollment.
- 6. Must have radiological progression on osimertinib treatment and can have either asymptomatic disease or symptomatic disease. In addition:
- 1. Must have measurable disease per RECIST 1.1.
- 2. Must have progression on osimertinib treatment as a single agent or in combination with other anti-cancer agents as their most recent treatment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04486833；登记信息更新于 2026-09-16。